DNA Repair Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 13.00 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
DNA Repair Drugs Market Analysis
The DNA repair drugs market is expected to register a CAGR of nearly 13% over the forecast period.
- COVID-19 impacted the growth of the DNA repair drugs market. The pandemic resulted in the disruption of services for patients suffering from cancer which has affected the demand for DNA repair drugs.
- For instance, according to a study published in the Journal of Breast Cancer in December 2021, it has been observed that the number of breast cancer diagnoses decreased by 9.9% during the pandemic period in South Korea. Thus, the decreased cancer diagnosis significantly reduced the demand for drugs. This has impacted the market growth during the pandemic. However, with the released restrictions and resumed diagnosis and treatment services, the studied market is anticipated to grow over the forecast period.
- Factors such as the growing burden of cancer worldwide and increasing research and development for novel drugs and treatments are boosting market growth. The incidence and prevalence of various types of cancer are growing rapidly due to lifestyle changes along with the factors that increase the risk of developing cancer, such as increasing consumption of alcohol and smoking, obesity, as well as a family history of cancer. This is expected to increase the demand as well as the need to develop effective and safe cancer drugs, hence propelling market growth.
- For instance, according to the data published by ICMR-National Cancer Registry Programme, in December 2022, about 1,461,427 cancer cases were reported in India in 2022 as compared to 1,426,447 cancer cases in 2021. Thus, the increased number of cancer cases among the population further fuel the demand for DNA repair drugs, hence propelling the market growth. Furthermore, the rising company focus on research and development of novel drugs for treating cancer are also contributing to the market growth. For instance, in August 2021, Artios Pharma raised EUR 129 million in a Series C round of funding to develop cancer drugs that target the DNA repair systems of cells.
- Moreover, as per an article published in Bioengineering Journal in July 2022, it has been found that innovative learning algorithms help in developing the desired chemical properties necessary for novel compounds, and the introduction of artificial intelligence (AI) has significantly advanced in silico design of anticancer drugs. Thus, the rapidly evolving AI technology is expected to have a large impact on the research and development activities for cancer drugs shortly. This is expected to boost market growth.
- Therefore, owing to the factors such as the high prevalence of cancer and growing company activities, the studied market is expected to grow over the forecast period. However, the strict regulation for product approvals is likely to impede the growth of the DNA repair drugs market over the forecast period.
DNA Repair Drugs Market Trends
Olaparib Segment is Expected to Hold a Significant Market Share in the DNA Repair Drugs Market Over Forecast Period
- Olaparib is a base-excision repair (BER) enzyme inhibitor that prevents poly-ADP ribose polymerase (PARP), which is involved in the repair of DNA damage caused by oxidative stress. Olaparib is sold under the brand name Lynparza. The advantages offered by Lynparza, such as it demonstrates a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reduced risk of cancer recurrences, second cancers or death, and high progression-free-survival rate, over the other DNA repair drugs (rucaparib, niraparib, and others) raises its adoption for the cancer treatment. This is anticipated to fuel the segment's growth over the forecast period.
- According to an article published in Expert Opinion on Pharmacotherapy in April 2021, it has been observed that Olaparib is approved following the administration of at least one line of new hormone therapy and does not require the prior taxane drug to have failed. It can be used for homologous recombination repair (HRR) mutations beyond breast cancer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2). This shows that olaparib can be used more frequently than other drugs, such as rucaparib, for patients with metastatic castration-resistant prostate cancer. This is expected to increase its adoption during prostate cancer treatment, which in turn is anticipated to fuel the segment growth over the forecast period.
- Furthermore, the rising product approvals raise the availability of effective DNA repair drugs in the market, which is also contributing to market growth. For instance, in March 2022, AstraZeneca and MSD's Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Therefore, owing to the factors such as rising product approvals and increasing adoption of olaparib due to its several advantages over other drugs, the studied segment is expected to grow over the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
- North America is expected to witness significant growth in the DNA repair drugs market over the forecast period owing to the factors such as the increasing focus on research and development, the growing number of investments in DNA repair research as well as the growing burden of cancer in the region.
- The increasing incidence and prevalence of various cancers among the population raise the demand for DNA repair drugs which in turn is anticipated to fuel the market growth. For instance, according to 2023 statistics published by ACS, about 1,958,310 new cancer cases (1,010,310 cases in males and 948,000 in females) are expected to be diagnosed in the United States in 2023 as compared to 1,918,030 cases in 2022.
- Additionally, as per 2022 statistics published by the Canada Cancer Society, an estimated 3,000 Canadian women were diagnosed with ovarian cancer in 2022. As per the same source, breast cancer is the most prevalent malignancy and the second-leading cause of cancer-related death in Canadian women. About 28,600 Canadian women were expected to be diagnosed with breast cancer in 2022, which represents 25% of all new cancer cases in women in 2022. Thus, the expected high number of cancer cases among the population is expected to increase the demand for effective treatment options, which in turn is anticipated to propel the market growth.
- Furthermore, the rising company activities in developing cancer drugs are also contributing to the market growth. For instance, in December 2022, Pfizer reported pre-approval single-patient expanded access (compassionate use) of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.
- Also, in October 2022, Pfizer reported positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide) plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. Therefore, owing to the factors such as the high burden of cancer and growing company activities, the studied market is expected to grow over the forecast period.
DNA Repair Drugs Industry Overview
The DNA repair drugs market is fragmented, with the presence of several global market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are AstraZeneca plc, Clovis Oncology, GlaxoSmithKline plc., Pfizer Inc., and Onxeo, among others.
DNA Repair Drugs Market Leaders
AstraZeneca plc
Clovis Oncology
GlaxoSmithKline plc.
Pfizer Inc.
Onxeo
*Disclaimer: Major Players sorted in no particular order
DNA Repair Drugs Market News
- December 2022: the European Union approved AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated.
- April 2022: Janssen Pharmaceutical submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT)* plus prednisolone, for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC).
DNorth America Repair Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer Worldwide
4.2.2 Increasing Research and Development for Novel Drugs and Treatment
4.3 Market Restraints
4.3.1 Strict Regulation for Product Approval
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Type
5.1.1 Olaparib
5.1.2 Rucaparib
5.1.3 Niraparib
5.1.4 Talazoparib
5.1.5 Other Drug Types
5.2 By Application
5.2.1 Ovarian Cancer
5.2.2 Fallopian Tube Cancer
5.2.3 Peritoneal Cancer
5.2.4 Breast Cancer
5.2.5 Other Applications
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Other Distribution Channel
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Onxeo
6.1.2 FoRx Therapeutics
6.1.3 Artios Pharma Limited
6.1.4 Merck KGaA
6.1.5 Breakpoint Therapeutics
6.1.6 Luciole Pharmaceuticals
6.1.7 AstraZeneca Plc
6.1.8 AbbVie
6.1.9 Johnson & Johnson
6.1.10 Pfizer Inc.
6.1.11 ClovisOncology Inc.
6.1.12 GlaxoSmithKline plc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
DNA Repair Drugs Industry Segmentation
As per the scope of the report, DNA repair drugs are the drugs majorly used in the treatment of cancers. DNA repair drugs are known to inhibit DNA repair enzymes and kill cancer cells with defects in DNA repair due to mutations in the DNA repair genes.
The DNA repair drugs market is segmented by drug type (olaparib, rucaparib, niraparib, talazoparib, and other drug types), application (ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and other application types), distribution channel (hospital pharmacies, retail pharmacies, and other distribution channels) and geography (North America, Europe, Asia-Pacific and the Rest of World).
The report offers the value (in USD million) for the above segments.
| By Drug Type | |
| Olaparib | |
| Rucaparib | |
| Niraparib | |
| Talazoparib | |
| Other Drug Types |
| By Application | |
| Ovarian Cancer | |
| Fallopian Tube Cancer | |
| Peritoneal Cancer | |
| Breast Cancer | |
| Other Applications |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Other Distribution Channel |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of World |
DNorth America Repair Drugs Market Research FAQs
What is the current DNA Repair Drugs Market size?
The DNA Repair Drugs Market is projected to register a CAGR of 13% during the forecast period (2024-2029)
Who are the key players in DNA Repair Drugs Market?
AstraZeneca plc, Clovis Oncology, GlaxoSmithKline plc., Pfizer Inc. and Onxeo are the major companies operating in the DNA Repair Drugs Market.
Which is the fastest growing region in DNA Repair Drugs Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in DNA Repair Drugs Market?
In 2024, the Asia-Pacific accounts for the largest market share in DNA Repair Drugs Market.
What years does this DNA Repair Drugs Market cover?
The report covers the DNA Repair Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the DNA Repair Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
DNA Repair Drugs Industry Report
Statistics for the 2024 DNA Repair Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. DNA Repair Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
